Clinical Trials Directory

Trials / Completed

CompletedNCT01846481

A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse

A Randomized, Double-blind, Placebo-controlled, Dose of RBP-8000 Following IV Cocaine to Evaluate the Pharmacokinetics Parameters of RBP-8000 and Cocaine and to Assess the Effects of Drug on Cocaine-induced Physiologic and Behavioral Effects in Cocaine Abusing Subjects

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Indivior Inc. · Industry
Sex
All
Age
21 Years – 50 Years
Healthy volunteers
Accepted

Summary

This is a randomized, 4-sequence, 2-period, double-blind, placebo controlled study in male and female subjects with an American Psychiatric Association Diagnostic and Statistical Manual DSM-IV-TR diagnosis of cocaine abuse.

Detailed description

There will be a 28-day screening period with eligible subjects remaining resident in the clinic from the evening before Day -1 up and until the morning of Day 9. On the morning of Day 1, a 50 mg intravenous (IV) infusion of cocaine will be administered over 10 minutes to all subjects. If none of the stopping criteria were met and no intervening safety concerns, subjects will be randomized to one of the treatment sequences on Day 3. On dosing days, Day 3 and Day 6, subjects will have fasted at least 8 hours before dosing of cocaine and either RBP-8000 200 mg, RBP-8000 100 mg or matching placebo.

Conditions

Interventions

TypeNameDescription
DRUGRBP-8000 100 mgRBP-8000 100 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
DRUGPlaceboIV infusion of Placebo administered 1 minute after cocaine infusion on either day 3 or 6.
DRUGCocaine50 mg intravenous (IV) dose of cocaine administered over 10 minutes on Days 1, 3 and 6.
DRUGRBP-8000 200 mgRBP-8000 200 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6

Timeline

Start date
2013-04-01
Primary completion
2013-06-01
Completion
2013-06-01
First posted
2013-05-03
Last updated
2016-09-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01846481. Inclusion in this directory is not an endorsement.